GME
GameStop Corp.
GME has a slight edge over MED overall, supported by stronger fundamentals and stronger valuation.
MED
Medifast, Inc.
MED has lower modeled downside risk, despite its lower overall score.
GME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Unavailable |
GME's profitability and cash flow are currently strong, and its revenue is stable. There isn't enough data to rate its balance sheet.
MED Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
MED's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
GME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.62 | — |
| Cheap | 18x | $27.96 | +9.1% |
| Forward | 38x | $25.62 | — |
| Fair | 43x | $66.84 | +161% |
| Expensive | 252x | $388 | +1414% |
Historical ranges are pointers, not guarantees.
GME's PE is in its cheap range at 17x. Analysts expect earnings to fall, which would put today's price at 38x next year's earnings, in its fair range.
MED PE Valuation
MED has no meaningful PE right now: it lost money over the past year.
GME Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect GME's earnings and revenue to decline, with profitability weakening.
MED Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
MED has the edge over GME on the outlook, with more favorable earnings and revenue expectations.
GME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -56% |
| Q3 2026 | $1.54 | +93% |
| Q2 2026 | $1.34 | +153% |
| Q1 2026 | $0.77 | +133% |
| Q4 2025 | $0.89 | +394% |
| Q3 2025 | $0.80 | +515% |
| Q2 2025 | $0.53 | +563% |
| Q1 2025 | $0.33 | +1550% |
| Q4 2024 | $0.18 | +$0.21 |
GME has the edge over MED on earnings quality, reporting a profit while its opponent remains loss making.
MED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.68 | -18500% |
| Q2 2026 | -$2.32 | -803% |
| Q1 2026 | -$1.82 | -$1.18 |
| Q4 2025 | -$1.70 | -995% |
| Q3 2025 | $0.02 | -97% |
| Q2 2025 | $0.33 | -88% |
| Q1 2025 | -$0.64 | -110% |
| Q4 2024 | $0.19 | -98% |
MED has swung to a loss: it lost $3.68 per share over the past year, after a profit the year before.
GME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $790.2M | -19% |
| Q2 2026 | $835.3M | +14% |
| Q1 2026 | $1.1B | -14% |
| Q4 2025 | $821M | -4.6% |
| Q3 2025 | $972.2M | +22% |
| Q2 2025 | $732.4M | -17% |
| Q1 2025 | $1.3B | -28% |
| Q4 2024 | $860.3M | -20% |
GME has the edge over MED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +13 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 12% | +6 points |
| Q4 2025 | 5% | +8.9 points |
| Q3 2025 | 6.8% | +9.6 points |
| Q2 2025 | -1.5% | +4.3 points |
| Q1 2025 | 6.2% | +3.1 points |
| Q4 2024 | -3.9% | -2.5 points |
GME has the edge over MED on profitability, with a higher operating margin.
MED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72M | -19% |
| Q2 2026 | $76.4M | -28% |
| Q1 2026 | $76M | -34% |
| Q4 2025 | $75.1M | -37% |
| Q3 2025 | $89.4M | -36% |
| Q2 2025 | $105.6M | -37% |
| Q1 2025 | $115.7M | -34% |
| Q4 2024 | $119M | -38% |
MED's revenue has slid since its 2022 peak: $72M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -27% | -22 points |
| Q2 2026 | -5.7% | -4.7 points |
| Q1 2026 | -4.3% | -3.2 points |
| Q4 2025 | -10% | -11 points |
| Q3 2025 | -4.6% | -6.1 points |
| Q2 2025 | -1% | +3.7 points |
| Q1 2025 | -1.1% | -5.6 points |
| Q4 2024 | 0.6% | -3.9 points |
MED's operating margin was −27% last quarter, down 22 points from the same quarter a year ago, near the bottom of its range since 2019.
GME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60.7M | -46% |
| Q2 2026 | $332.9M | +76% |
| Q1 2026 | $187.4M | +18% |
| Q4 2025 | $107M | +435% |
| Q3 2025 | $113.3M | +73% |
| Q2 2025 | $189.6M | +$304.3M |
| Q1 2025 | $158.8M | +$177.5M |
| Q4 2024 | $20M | +80% |
GME has the edge over MED on cash generation, producing positive trailing cash flow while its opponent burns cash.
MED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $728K | +$5.5M |
| Q1 2026 | -$836K | -144% |
| Q4 2025 | -$6.6M | +$603K |
| Q3 2025 | $10.8M | +40% |
| Q2 2025 | -$4.8M | -143% |
| Q1 2025 | $1.9M | -65% |
| Q4 2024 | -$7.2M | -176% |
MED's free cash flow has turned negative after years in the green: −$4M over the past year.
GME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | +8.4% | +46.1M shares |
| 3 years | +94% | +288M shares |
| 5 years | +104% | +302M shares |
| Available history | +80% | +264M shares |
GME has 593M diluted shares, up 8.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | $21.8M |
| Q4 2019 | $114M |
MED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +46K shares |
| 1 year | +1.7% | +190K shares |
| 3 years | +2.3% | +248K shares |
| 5 years | -5.1% | -604K shares |
| Available history | -7.7% | -936K shares |
MED has the edge over GME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.6M |
GME Net Leverage
MED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -2,976.8x | Net Cash |
| Q3 2025 | -12.1x | Net Cash |
| Q2 2025 | -7.2x | Net Cash |
| Q1 2025 | -14.3x | Net Cash |
| Q4 2024 | -5.8x | Net Cash |
| Q3 2024 | -4.9x | Net Cash |
| Q2 2024 | -2.3x | Net Cash |
| Q1 2024 | -1.0x | Net Cash |
MED has more cash than debt.
GME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 68.5 | Neutral |
GME's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
MED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 72.6 | Neutral |
MED's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
GME PE vs Consumer Cyclical Sector
| Metric | GME | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7.7% below |
| PE % | 15 | 47 | 32 pts below |
GME is trading at 17x earnings, in line with the Consumer Cyclical sector's median of 18x.
MED PE vs Consumer Cyclical Sector
| Metric | MED | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MED has no meaningful PE right now: it lost money over the past year.
GME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.2 | 1.8% above |
| 20 week MA | $22.4 | 15% above |
| 50 week MA | $22.6 | 13% above |
| 100 week MA | $24.0 | 7% above |
| 200 week MA | $21.8 | 17% above |
GME has the edge over MED on trend strength, trading above more of its moving averages.
MED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 6% above |
| 20 week MA | $11.7 | 10% above |
| 50 week MA | $11.4 | 13% above |
| 100 week MA | $12.6 | 1.9% above |
| 200 week MA | $35.4 | 64% below |
MED has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 64% below its 200-week average.
GME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.48 | $5.04 | +241% |
| 2021 | $5.04 | $38.0 | +655% |
| 2022 | $38.0 | $20.1 | -47% |
| 2023 | $20.1 | $17.5 | -13% |
| 2024 | $17.5 | $32.2 | +84% |
| 2025 | $32.2 | $21.1 | -35% |
| 2026 YTD | $21.1 | $25.6 | +21% |
GME has the edge over MED on returns for 2026, with the stronger performance.
MED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $196.7 | +82% |
| 2021 | $196.7 | $204.2 | +3.8% |
| 2022 | $204.2 | $117.1 | -43% |
| 2023 | $117.1 | $67.2 | -43% |
| 2024 | $67.2 | $17.6 | -74% |
| 2025 | $17.6 | $11.0 | -37% |
| 2026 YTD | $11.0 | $12.9 | +16% |
MED has finished four years in a row lower, and it's up 16% so far in 2026.